Jacobs Levy Equity Management Inc. Sells 189,881 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Jacobs Levy Equity Management Inc. lessened its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 66.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,379 shares of the company's stock after selling 189,881 shares during the period. Jacobs Levy Equity Management Inc.'s holdings in Amneal Pharmaceuticals were worth $810,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Rothschild Investment LLC bought a new stake in Amneal Pharmaceuticals in the 2nd quarter worth approximately $26,000. Gladius Capital Management LP bought a new stake in Amneal Pharmaceuticals in the 3rd quarter worth approximately $37,000. DekaBank Deutsche Girozentrale bought a new stake in Amneal Pharmaceuticals in the 2nd quarter worth approximately $42,000. nVerses Capital LLC bought a new stake in Amneal Pharmaceuticals in the 2nd quarter worth approximately $62,000. Finally, Xponance Inc. bought a new stake in shares of Amneal Pharmaceuticals during the 2nd quarter valued at $65,000. Institutional investors own 31.82% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on AMRX. Truist Financial boosted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd. Piper Sandler boosted their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price objective for the company in a research report on Friday, September 6th. Barclays boosted their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an "overweight" rating in a research report on Tuesday, August 13th. Finally, StockNews.com raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Monday, November 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of "Buy" and a consensus target price of $10.00.

Insider Activity at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business's stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 17.46% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Trading Up 0.7 %

Shares of AMRX traded up $0.06 during trading hours on Tuesday, reaching $8.15. 883,804 shares of the stock traded hands, compared to its average volume of 1,392,724. Amneal Pharmaceuticals, Inc. has a 52-week low of $4.46 and a 52-week high of $9.48. The company's 50-day moving average price is $8.54 and its two-hundred day moving average price is $7.87. The company has a market cap of $2.53 billion, a P/E ratio of -11.99 and a beta of 1.12.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.